Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
My Lists

Addition Technology  Acquired by AstraZeneca (2012 $ 1,000,000,000 )


Website Company Summary Management Team



Business description: Restoring quality of life through better vision...Intacs corneal implants is an FDA approved option for the keratoconus patient that is in-between contact lenses and a corneal transplant! Keratoconus is a progressive eye disease, which causes a thinning of the cornea, the clear front surface of the eye. As keratoconus progresses, the quality of one's vision deteriorates and contact lenses or glasses no longer become a satisfactory solution for most people. Historically, a corneal transplant has been the only option – until Intacs! Intacs corneal implants are an exciting option for individuals experiencing an intolerance to contact lens and are facing a corneal transplant. Intacs corneal implants may be the best possible option to stabilize the cornea, improve vision and potentially defer the need for a corneal transplant. Intacs corneal implants are indicated for use in the correction of nearsightedness and astigmatism associated with keratoconus where contact lenses and glasses are no longer suitable. Intacs corneal implants are approved by the FDA for keratoconus under a Humanitarian Device Exemption (HDE).

Ownership: Acquired by AstraZeneca (2012 $ 1,000,000,000 )

Last Tweets


Last Mentions

Record updated: May 2006
Ownership: Acquired by AstraZeneca (2012 $ 1,000,000,000 )